u/tuva_kirchner

The two decisions that this whole board turns on, kept apart.

Disagreeing with this bit: that advice predates the change in compounded arrangements.

the hepatic data is what makes this compound different from the others

Careful, personal importation provisions are narrow and specific and the general version circulating here is wrong.

Same view. The second-level appeal is where mine turned, after a first-level denial that looked final.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

losing weight slower does not automatically preserve more lean mass

Agreed on quoting the claim alongside the result. Half the arguments here are two people comparing to different reference numbers.

Subsidy criteria and authority requirements are published. For eligibility questions those documents are authoritative and this board is not.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Disagree with the "more water is safer" framing. It is not safer, it is just a different number to divide by.

Registration by the therapeutic goods regulator establishes that a product may be supplied. Subsidy listing is a separate decision about public funding, with its own criteria and its own timetable.

the weight numbers are secondary to what this is being developed for

aim the stream at the glass wall, not at the cake

Asked for the policy bulletin by number and wrote the appeal against its criteria line by line. Approved on the second level after a flat first-level denial.

Push back: three tests on one lot is one lot. It tells you about that lot and almost nothing about the next one.

three lots beats three tests on one lot

PBS criteria are published and searchable

That is an escalation schedule for an unapproved compound and this board does not host those.

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

A denial letter is required to state a reason and to reference the criterion applied. That reference is the handle: request the clinical policy document by its identifier and answer it point by point.

the trend across lots is worth more than any single figure

Three scans over eighteen months, same machine, same conditions. Only the third one made the first two interpretable.

I would not read across from the obesity programmes. Different population, different endpoint, different question.

Yes. Lean mass change during weight loss is expected; the useful question is the proportion, not whether it happens.

read the histology endpoint definitions before quoting a response rate

say which state only if it matters, but always say which country

What is the appeal deadline on the letter?

Asked for the policy bulletin by number and wrote the appeal against its criteria line by line. Approved on the second level after a flat first-level denial.

employer plans and individual plans are different fights

Are you comparing against your own baseline or against a published average?

Have the lifts held, dropped, or moved around?

DEXA has a real error margin and people quote it to one decimal

Missed a deadline because I counted from when I opened the envelope. That mistake cost me an entire cycle.

Left up and flaired Explainer — the numbers in this one check out.

Disagreeing with this line only: adding more water is not a safety margin, it is a different divisor.

resistance training first, cardio if there is time left

say which state only if it matters, but always say which country

losing weight slower does not automatically preserve more lean mass

a U-100 syringe reads 100 units to the millilitre, every time

Split one vial between Janoshik and VendorInvestigate. The two numbers were within half a point of each other and I stopped worrying about which lab to trust.